Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De Sells 7,373 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the sale, the executive vice president now directly owns 79,460 shares of the company’s stock, valued at $726,264.40. The trade was a 8.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Verneuil Vanina De also recently made the following trade(s):

• On Monday, December 2nd, Verneuil Vanina De sold 76 shares of Vir Biotechnology stock. The shares were sold at an average price of $8.22, for a total transaction of $624.72.

Vir Biotechnology Trading Down 11.8 %

Shares of NASDAQ VIR traded down $1.09 during trading hours on Thursday, reaching $8.11. The stock had a trading volume of 1,676,795 shares, compared to its average volume of 2,509,073. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -2.08 and a beta of 0.63. The firm has a 50-day moving average of $9.42 and a 200-day moving average of $8.50. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. On average, equities analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on VIR shares. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research report on Thursday. JPMorgan Chase & Co. raised their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research report on Thursday, January 9th. Leerink Partners upped their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Barclays decreased their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Vir Biotechnology has an average rating of “Moderate Buy” and a consensus target price of $34.83.

Institutional Investors Weigh In On Vir Biotechnology

A number of large investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Vir Biotechnology by 29.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 181,325 shares of the company’s stock valued at $1,331,000 after purchasing an additional 40,954 shares during the last quarter. Woodline Partners LP acquired a new position in shares of Vir Biotechnology during the 4th quarter valued at $991,000. Two Sigma Advisers LP boosted its position in shares of Vir Biotechnology by 74.8% in the fourth quarter. Two Sigma Advisers LP now owns 74,800 shares of the company’s stock worth $549,000 after buying an additional 32,000 shares during the period. Stonepine Capital Management LLC acquired a new stake in Vir Biotechnology in the fourth quarter valued at approximately $1,205,000. Finally, Sphera Funds Management LTD. grew its holdings in Vir Biotechnology by 523.4% during the 4th quarter. Sphera Funds Management LTD. now owns 581,829 shares of the company’s stock valued at $4,271,000 after purchasing an additional 488,500 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).